Search people, articles, bills, and more
This bill is important because it directly impacts the cost of prescription drugs for millions of Americans on Medicare, as well as the overall spending of the Medicare program. If this bill passes, prices for many widely used prescription drugs (small-molecule drugs) could remain higher for an additional four years compared to current law, delaying potential savings for patients and for Medicare itself.
For voters, this means considering the potential benefits of encouraging drug innovation by giving companies more time to earn back their investment versus the costs of higher drug prices for a longer period. If the bill does not pass, the current schedule for drug price negotiation will continue, with small-molecule drugs becoming eligible for negotiation after 7 years.
No reactions yet. Be the first to weigh in.
This bill is important because it directly impacts the cost of prescription drugs for millions of Americans on Medicare, as well as the overall spending of the Medicare program. If this bill passes, prices for many widely used prescription drugs (small-molecule drugs) could remain higher for an additional four years compared to current law, delaying potential savings for patients and for Medicare itself.
For voters, this means considering the potential benefits of encouraging drug innovation by giving companies more time to earn back their investment versus the costs of higher drug prices for a longer period. If the bill does not pass, the current schedule for drug price negotiation will continue, with small-molecule drugs becoming eligible for negotiation after 7 years.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)